公司資料
Apogee Therapeutics 股價、新聞與催化劑
- 股票代碼:
- APGE
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
134.59 USD (+0.03%)
收盤價
最後更新: 2026年8月17日
5.93B USD
市值
股價為何變動
As of Aug 17, 2026, APGE was little changed and closed at $134.59. No new same-company headline was identified in the current news window.
公司概覽
Long-Acting I&I Biologics
Apogee Therapeutics develops optimized biologics for inflammatory and immunologic diseases. Its candidates are engineered for differentiated efficacy and extended dosing intervals across large chronic indications.
Zumilokibart
Zumilokibart is a long-acting antibody targeting IL-13 and is the company's lead program. Its extended half-life is intended to support dosing at intervals measured in months.
Atopic-Dermatitis Program
The APEX Phase 2 program evaluates induction and maintenance regimens of zumilokibart in moderate-to-severe atopic dermatitis to support Phase 3 dose selection.
Asthma and Eosinophilic Esophagitis
Following Phase 1b asthma results, Apogee is planning broader development of zumilokibart in asthma and eosinophilic esophagitis, treating the antibody as a pipeline-in-a-product.
Broader I&I Portfolio
The company is also building biologics for chronic obstructive pulmonary disease and other inflammatory conditions, seeking to improve the dosing and efficacy profiles of validated therapeutic targets.
未來催化劑
- Initiation of Phase 3 studies of zumilokibart in atopic dermatitis in 2026.
- Initiation of the ELEVATE Phase 2a study of zumilokibart in eosinophilic esophagitis in the second half of 2026.
- Interim data from the Phase 1b APG279 head-to-head study in atopic dermatitis in the second half of 2026.
- Initiation of the potentially registrational ASPIRE Phase 2b asthma study in the first half of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。